Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04946578
Other study ID # Sport and microbiota
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 24, 2020
Est. completion date September 30, 2021

Study information

Verified date June 2021
Source Maastricht University
Contact Freddy Troost, Dr.
Phone +31(0)43 3884296
Email f.troost@maastrichtuniversity.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the effect of a six-week period personalised food intervention with prebiotic supplementation on intense exercise performance in healthy, recreationally active adults.


Description:

The study conforms to a randomized, single-blinded, placebo-controlled parallel study design. a prebiotic supplement will be selected based on a participants gut microbiota. 1 sachet of prebiotic or placebo will be given twice a day over a period of 6 weeks. Before the start of the study, a VO2max test will be performed. Subjects will bring faecal samples which is collected at home. A time to exhaustion of approximately 80% of their VO2max will be performed at baseline and after the 6 weeks intervention period.


Recruitment information / eligibility

Status Recruiting
Enrollment 34
Est. completion date September 30, 2021
Est. primary completion date August 23, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Male or female 18 - 40 y - BMI range 18.5 - 25 kg/m2 - Recreational active (performing non-competitive physical endurance exercise at least two times per week with a minimum duration of 60 minutes per exercise bout) Exclusion Criteria: - Smoking - Performing regular resistance training (3+ times per week, carrying out progressive overload training) - Subject following an overly imbalanced or restrictive diet as per nutritional advice - Participants who received antibiotics in the 90 days prior to the start of the study - Self-admitted lactose intolerance - Administration of probiotic or prebiotic supplements in the 14 days prior to the study

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Prebiotic
6 weeks of prebiotic supplementation twice a day
Other:
Placebo
6 weeks of maltodextrin supplementation twice a day

Locations

Country Name City State
Netherlands Maastricht University Maastricht Limburg

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Exhaustion Time on cycle ergometer until exhaustion From baseline to end of the study (up to max 45 days)
Secondary Gut microbiota composition Composition of the gut microbiota by faecal sample analysis From baseline to end of the study (up to max 45 days)
Secondary Plasma short chain fatty acids Short chain fatty acids in plasma From baseline to end of the study (up to max 45 days)
Secondary Blood glucose Fasted blood glucose From baseline to end of the study (up to max 45 days)
Secondary Insulin Fasted insulin From baseline to end of the study (up to max 45 days)
Secondary Intestinal permeability by sugar test Intestinal permeability measured by a sugar drink test From baseline to end of the study (up to max 45 days)
See also
  Status Clinical Trial Phase
Recruiting NCT05288790 - Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT Phase 2
Recruiting NCT05963659 - Nitrate Modulates Cognitive Impairment Via Oral Microbiota. N/A
Completed NCT04130321 - Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans N/A
Recruiting NCT05929976 - InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Withdrawn NCT04230746 - Effect of Antibiotics on Urinary Microbiome Early Phase 1
Active, not recruiting NCT06289283 - Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
Recruiting NCT05714566 - Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients
Enrolling by invitation NCT06225336 - Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia) Phase 1
Recruiting NCT05068362 - Auricular Reconstruction in Microtia by Medpor Implant Following Tissue Expansion N/A
Completed NCT02224677 - Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)
Not yet recruiting NCT05615116 - Clinical Study on the Distribution of Digestive Tract Microbiota Before and After Ileocecal Resection in Crohn's Disease
Enrolling by invitation NCT06220994 - the Gut Microbiome and Metabolomics in Chronic Lower extreMities Threatening Ischemia
Completed NCT00958802 - Tissue Engineering Microtia Auricular Reconstruction: in Vitro and in Vivo Studies Phase 0
Recruiting NCT06087874 - Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice Phase 2
Suspended NCT03624608 - Evaluation of the Auryzon Devices in the Optimization of Ear and Nose Reconstruction Procedures N/A
Not yet recruiting NCT06394687 - The Digestion of Protein Powders in Healthy Participants Using SIMBA and LIMBA Capsule N/A
Completed NCT05417360 - Akkermansia and Weight Maintenance N/A
Recruiting NCT02518035 - Silicone Gel to Improve Scar in Microtia Patients Phase 4
Recruiting NCT06078566 - Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 Phase 1/Phase 2
Recruiting NCT06072040 - Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia Phase 1/Phase 2